Navigation Links
Ranbaxy Launches Authorized Generic Version of Rocaltrol(R)
Date:9/2/2009

oducts in the U.S. healthcare system.

Ranbaxy Laboratories Limited, headquartered in India, is an integrated, research based, international pharmaceutical company producing a wide range of quality, affordable generic medicines, trusted by healthcare professionals and patients across geographies. Ranbaxy's continued focus on R&D has resulted in several approvals in developed markets and significant progress in New Drug Discovery Research. The Company's foray into Novel Drug Delivery Systems has led to proprietary "platform technologies", resulting in a number of products under development. The Company is serving its customers in over 125 countries and has an expanding international portfolio of affiliates, joint ventures and alliances, ground operations in 49 countries and manufacturing operations in 11 countries. Ranbaxy is a subsidiary of Daiichi Sankyo Company, Ltd.

Validus Pharmaceuticals LLC is focused on acquiring, developing and marketing effective, underutilized branded products in specialty therapeutic areas. During the past three years, the company has successfully acquired four products with specific therapeutic advantages that provide a current revenue stream. Validus seeks to acquire drug assets that are approved by the FDA and have well defined and accepted clinical utility relevant to today's practice of medicine. Validus is a portfolio company of Wood Creek Capital Management, LLC, a registered investment advisor that is focused on alternative investments. For more information about Validus Pharmaceuticals, visit www.validuspharma.com.

    CONTACTS: Charles M. Caprariello
              Vice President, Corporate Communications
              Ranbaxy Inc.
              (609) 720-5615

              Edwige Buteau
              RF Binder Partners Inc.
              (212) 994-7517

              Andrea Pavone
              RF Binder Partners Inc.
              (212) 994-7568
'/>"/>
SOURCE Ranbaxy Pharmaceuticals Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine news :

1. Ranbaxy Receives Final Approval to Manufacture and Market Glycopyrrolate Tablets
2. Ranbaxy Receives Final Approval To Market Sumatriptan Succinate Tablets
3. Ranbaxy Secures Final FDA Approval for Quinapril Hydrochloride + Hydrochlorothiazide Tablets
4. Press Statement Issued by Ranbaxy Laboratories Limited
5. Cipher Pharmaceuticals announces U.S. distribution and supply agreement with Ranbaxy for CIP-ISOTRETINOIN
6. Ranbaxy and Pfizer Settle Lipitor Litigation Worldwide
7. Ranbaxy to Bring in Daiichi Sankyo as Majority Partner; Strategic Combination Creates Innovator and Generic Pharma Powerhouse
8. Ranbaxy Receives Final Approval to Manufacture and Market Cetirizine Hydrochloride Oral Solution
9. Ranbaxy Gains Approval to Manufacture and Market Cefuroxime Axetil for Oral Suspension
10. Ranbaxy Receives Final Approval to Manufacture and Market Cetirizine Hydrochloride Tablets (OTC), 5mg and 10mg
11. Ranbaxy Receives Tentative Approval For Valsartan Tablets
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/25/2014)... York, New York (PRWEB) December 25, 2014 ... the 2010 DePuy ASR hip recall ( http://www.consumerinjurylawyers.com/DePuy/ ) ... LLP reports. According to an Order issued in the ... 20th, the Court will convene an open conference on ... Building and United States Courthouse in West Palm Beach, ...
(Date:12/25/2014)... “Every three months the trends for ... evening dress will be one of the hottest styles in ... says. Today, the company releases 26 A-line sweetheart evening dresses, ... off. , “We are trying our best to help ... latest designs. Along with affordable prices, we provide discounted delivery ...
(Date:12/25/2014)... 26, 2014 Recently, iFitDress.com, the popular online ... has announced its new selection of black one-shoulder cocktail ... sale now; they are available at discounted prices, up to ... promotion will last for three weeks only. You know, we ... who are interested in our new items can visit our ...
(Date:12/25/2014)... 26, 2014 Recently, Dylan Queen, a ... excitedly released its collection of discounted prom dresses, most ... a senior spokesman of the company, the promotion is ... promotion is to expand the UK market. , The ... different colors, lengths, and styles: A-line strapless, empire strapless ...
(Date:12/25/2014)... Los Angeles, CA (PRWEB) December 25, 2014 ... Blaise Dolcemaschio was created in honor of a true ... premiere at two film festivals including the 24 hours of ... Film Festival in Bangladesh. , Actress, screenwriter and ... and helped produce this film together with her husband, ...
Breaking Medicine News(10 mins):Health News:Federal Court Overseeing DePuy ASR Hip Lawsuit Set to Convene Conference in January, Bernstein Liebhard LLP Reports 2Health News:Federal Court Overseeing DePuy ASR Hip Lawsuit Set to Convene Conference in January, Bernstein Liebhard LLP Reports 3Health News:iFitDress.com: Black One-Shoulder Cocktail Dresses for 2015 2Health News:Dylan Queen: Cheap Prom Dresses for the UK Market 2Health News:The True 9/11 Hero Story “Color of Honor” Premieres in Germany and Bangladesh: Luciana Lagana Plays the Mother of the Lead and Co-Produces with Blaise Dolcemaschio. 2Health News:The True 9/11 Hero Story “Color of Honor” Premieres in Germany and Bangladesh: Luciana Lagana Plays the Mother of the Lead and Co-Produces with Blaise Dolcemaschio. 3
... Kabi Pty Ltd, one of Australia,s fastest growing and ... (Robotic IV Automation) - a self-contained unit for filling ... (IH Systems) to consolidate its IV preparation. Pharmatel Fresenius ... in June 2009. , The RIVA System and Pharmatel ...
... Feb. 11 Naturs Design, Inc., a privately held ... the revolutionary product that virtually eliminates all of the ... for sleep apnea. Unfortunately, CPAP therapy hasn,t always been ... reports that "many CPAP users never continue therapy beyond ...
... Gynecologic Oncologists, 40th Annual Meeting on Women,s Cancer Proves ... Pa., Feb. 11 New data presented on Saturday ... Oncologists, 40th Annual Meeting on Women,s Cancer demonstrated the ... CA125 blood test results and the Risk of Ovarian ...
... 11 Rising Medical Solutions, Inc. (Rising), ... management organization, announced today that it has ... Accreditation from URAC, a Washington, DC-based health ... quality standards for the health care industry.(Logo: ...
... announced today that Laurence Debroux is ... (CSO).In light of the implementation of the Group,s ... the position of Chief Strategic Officer at the ... business development and acquisition activities as well as ...
... Feb. 11 The Quantum Group, Inc. ( NYSE ... that Pete Martinez, Senior Vice President and Chief Technology ... the St. Thomas University Healthcare Seminar later ... Economic Times." Martinez will contribute to the event ...
Cached Medicine News:Health News:Australia's Leading Oncology Drug Compounder Chooses RIVA System 2Health News:Husband From Small Town May Have Found Solution to Sleep Industry's 20-Year Compliance Problem 2Health News:Biomarker Combination and Risk of Ovarian Malignancy Algorithm (Roma(TM)) Demonstrates Accuracy in Detecting Ovarian Cancer 2Health News:Biomarker Combination and Risk of Ovarian Malignancy Algorithm (Roma(TM)) Demonstrates Accuracy in Detecting Ovarian Cancer 3Health News:Rising Medical Solutions Receives URAC Workers' Compensation Utilization Management Accreditation 2Health News:Rising Medical Solutions Receives URAC Workers' Compensation Utilization Management Accreditation 3Health News:Laurence Debroux Appointed Chief Strategic Officer (CSO) 2Health News:Quantum Executive Pete Martinez Invited to Participate in University Health Seminar 2Health News:Quantum Executive Pete Martinez Invited to Participate in University Health Seminar 3Health News:Quantum Executive Pete Martinez Invited to Participate in University Health Seminar 4
(Date:12/24/2014)... , Dec. 24, 2014 /CNW/ - ... is being recalled after Health Canada tests confirmed it ... health risks (beta-methylphenethylamine and phenylpropylmethylamine). The distributor, Empire Health ... recalling the product from retail stores across ... building purposes, including for weight loss and increased energy. ...
(Date:12/24/2014)... Dec. 24, 2014  Novastem, a leader in ... patient in its study for ischemic stroke at ... Association, ischemic strokes account for 87 percent of ... patients in the study, entitled "Internal Research Protocol ... Mesenchymal Stem Cells and Intrathecal Administration of Neural ...
(Date:12/24/2014)... -- Actavis plc (NYSE: ACT ) today ... response letter from the U.S. Food and Drug ... for the fixed-dose combination (FDC) of nebivolol and ... Photo - http://photos.prnewswire.com/prnh/20130124/NY47381LOGO ... a complete response letter, Actavis remains committed to ...
Breaking Medicine Technology:"Jetfuel Superburn" recalled after Health Canada tests find undeclared drug ingredients 2Novastem Treats First Patient Using Stemedica's Mesenchymal and Neural Stem Cell Combination Therapy for Ischemic Stroke 2Novastem Treats First Patient Using Stemedica's Mesenchymal and Neural Stem Cell Combination Therapy for Ischemic Stroke 3Novastem Treats First Patient Using Stemedica's Mesenchymal and Neural Stem Cell Combination Therapy for Ischemic Stroke 4Actavis Confirms Complete Response Letter for Nebivolol/Valsartan Fixed-Dose Combination for Hypertension 2Actavis Confirms Complete Response Letter for Nebivolol/Valsartan Fixed-Dose Combination for Hypertension 3Actavis Confirms Complete Response Letter for Nebivolol/Valsartan Fixed-Dose Combination for Hypertension 4
... Corporation (NYSE: SYK ) reported operating results for ... Third Quarter Highlights Net sales ... to $1,768 million Orthopaedic Implants sales increased 1.3% on ... Equipment sales increased 16.3% on a constant currency basis (16.1% ...
... Calif., Oct. 19 ThermoGenesis Corp. (Nasdaq: ... services that process and store adult stem cells, said ... agreement for its Res-Q™ 60 BMC (Res-Q) System with ... point-of-care cardiovascular therapies. Under the agreement, ...
Cached Medicine Technology:Stryker Reports 7% Sales Growth, 14% Adjusted Net Earnings Growth for Quarter Ended September 30, 2010 2Stryker Reports 7% Sales Growth, 14% Adjusted Net Earnings Growth for Quarter Ended September 30, 2010 3Stryker Reports 7% Sales Growth, 14% Adjusted Net Earnings Growth for Quarter Ended September 30, 2010 4Stryker Reports 7% Sales Growth, 14% Adjusted Net Earnings Growth for Quarter Ended September 30, 2010 5Stryker Reports 7% Sales Growth, 14% Adjusted Net Earnings Growth for Quarter Ended September 30, 2010 6Stryker Reports 7% Sales Growth, 14% Adjusted Net Earnings Growth for Quarter Ended September 30, 2010 7Stryker Reports 7% Sales Growth, 14% Adjusted Net Earnings Growth for Quarter Ended September 30, 2010 8ThermoGenesis Announces Platelet Rich Plasma (PRP) Res-Q Cardiovascular Licensing Agreement 2ThermoGenesis Announces Platelet Rich Plasma (PRP) Res-Q Cardiovascular Licensing Agreement 3
For children up to 4 years of age 11 mm internal diameter of the cornea part. Designed to work with argon/YAG Lasers....
... capture and management system that acquires extremely ... Angiography images. It interfaces with most current ... from any ophthalmic device with video, digital ... the features of EyeCap RI, with further ...
The Haag-Streit 81 D lens is a powerful tool for biomicroscopy as well as laser treatment of the fundus. Due to its asymmetric configuration it provides better observation parameters combined with im...
... mirrored surfaces, which each incline at an ... have been cut into the 17 mm ... to examine the opposite iridocorneal angle without ... form of the angle of the iris ...
Medicine Products: